Volume 56, Issue 2, Pages (August 2009)

Slides:

Advertisements

Similar presentations

Volume 53, Issue 3, Pages (March 2008)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 71, Issue 1, Pages (January 2017)

Volume 74, Issue 2, Pages (August 2018)

Volume 64, Issue 4, Pages (October 2013)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 51, Issue 4, Pages (April 2007)

Volume 61, Issue 2, Pages (February 2012)

Volume 52, Issue 3, Pages (September 2007)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 63, Issue 4, Pages (April 2013)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 51, Issue 1, Pages (January 2007)

Volume 54, Issue 4, Pages (October 2008)

Volume 63, Issue 6, Pages (June 2013)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 70, Issue 5, Pages (November 2016)

Counselling the Prostate Cancer Patient

Volume 54, Issue 2, Pages (August 2008)

Volume 66, Issue 6, Pages (December 2014)

Volume 64, Issue 6, Pages (December 2013)

Volume 52, Issue 2, Pages (August 2007)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 2, Pages (August 2014)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 65, Issue 6, Pages (June 2014)

Tillmann Loch, Pat Fox Fulgham European Urology

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Volume 71, Issue 5, Pages (May 2017)

Testicular Cancer Variations in Time and Space in Europe

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Volume 54, Issue 6, Pages (December 2008)

Volume 66, Issue 6, Pages (December 2014)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Volume 54, Issue 3, Pages (September 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 56, Issue 2, Pages 392-394 (August 2009) Reduction of Serum Prostate-Specific Antigen Levels following Varicella-Zoster Infection and Valaciclovir Treatment in Prostate Cancer Roy R. Jurhill, Haitze van der Veen, Geert J.L.H. van Leenders, Paul C.M.S. Verhagen European Urology Volume 56, Issue 2, Pages 392-394 (August 2009) DOI: 10.1016/j.eururo.2009.02.025 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Patient A: Prostate needle biopsy showing a Gleason 3+4=7 prostate carcinoma. European Urology 2009 56, 392-394DOI: (10.1016/j.eururo.2009.02.025) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Patient A: Prostate-specific antigen (PSA) levels and events. Note the decrease in PSA by 1.2μg/l after varicella-zoster virus (VZV) reactivation and valaciclovir (vACV) treatment. European Urology 2009 56, 392-394DOI: (10.1016/j.eururo.2009.02.025) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Patient B: Prostate needle biopsy showing a Gleason 3+5=8 prostate carcinoma. European Urology 2009 56, 392-394DOI: (10.1016/j.eururo.2009.02.025) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 4 Patient B: Prostate-specific antigen (PSA) levels and events. Note that PSA has remained <0.01μg/l since the varicella-zoster virus (VZV) reactivation and valaciclovir (vACV) treatment. European Urology 2009 56, 392-394DOI: (10.1016/j.eururo.2009.02.025) Copyright © 2009 European Association of Urology Terms and Conditions